$TMO

CASPER MARC N sold $2.9M of TMO (indirect holdings)

CASPER MARC N (Chairman & CEO) sold 5,000 indirectly-held shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $575.23 ($566.26–$577.56, $2.88M total) across 11 trades on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 7, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($2.876M) and execution window ($566.26 to $577.56) under a pre-arranged plan, which can slightly influence short-term sentiment but is not a fundamental update.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The transaction is indirect and spread across 11 trades, which further reduces interpretability versus a single large, discretionary sale.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-07, sale executed 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported from an officer/director role with an indicated 10b5-1 plan.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO Casper Marc N sold $2.88M of TMO shares via a 10b5-1 plan on 2026-08-05 at $566.26 to $577.56.

Expected impact

Likely limited near-term impact; any reaction should be small and fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with stated 10b5-1 pre-arrangement, which typically reduces the informational content versus discretionary selling.

Market effects

Minimal; insider selling at a single large healthcare/life-sciences tools name does not materially change sector fundamentals.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can coincide with planned liquidity needs and does not necessarily reflect bearish views; traders may overreact to the headline.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider sale disclosure.

  • CASPER MARC N

    Chairman & CEO who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DALMed

CNBC’s ‘Final Trades’: Delta Air, Target, Thermo Fisher Scientific - Delta Air Lines (NYSE:DAL)

CNBC's 'Final Trades' featured picks from analysts, including Delta Air Lines (DAL) for its strong Q2 earnings, Thermo Fisher Scientific (TMO) for its raised FY2026 guidance, and Target (TGT) for its better-than-expected Q2 results. Interactive Brokers (IBKR) was also mentioned for its new Latin America funding solution. DAL +1.4%, TMO -0.1%, TGT -3.8%, IBKR +5.5%.

$BIIBMed

Eyes on Asia: Tanabe Pharma, KYAN Technologies, Biogen

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.